These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
101 related articles for article (PubMed ID: 37016030)
1. Transport of Designed Ankyrin Repeat Proteins through reconstituted human bronchial epithelia and protection against SARS-CoV-2. Künzi L; Ryter S; Cornelius A; Leni Z; Baumlin N; Salathe M; Walser M; Engler O; Geiser M Sci Rep; 2023 Apr; 13(1):5537. PubMed ID: 37016030 [TBL] [Abstract][Full Text] [Related]
2. Thermostable designed ankyrin repeat proteins (DARPins) as building blocks for innovative drugs. Schilling J; Jost C; Ilie IM; Schnabl J; Buechi O; Eapen RS; Truffer R; Caflisch A; Forrer P J Biol Chem; 2022 Jan; 298(1):101403. PubMed ID: 34793836 [TBL] [Abstract][Full Text] [Related]
3. A potent and broad neutralization of SARS-CoV-2 variants of concern by DARPins. Chonira V; Kwon YD; Gorman J; Case JB; Ku Z; Simeon R; Casner RG; Harris DR; Olia AS; Stephens T; Shapiro L; Bender MF; Boyd H; Teng IT; Tsybovsky Y; Krammer F; Zhang N; Diamond MS; Kwong PD; An Z; Chen Z Nat Chem Biol; 2023 Mar; 19(3):284-291. PubMed ID: 36411391 [TBL] [Abstract][Full Text] [Related]
5. Inhibition of coronavirus infection by a synthetic STING agonist in primary human airway system. Zhu Q; Zhang Y; Wang L; Yao X; Wu D; Cheng J; Pan X; Liu H; Yan Z; Gao L Antiviral Res; 2021 Mar; 187():105015. PubMed ID: 33444702 [TBL] [Abstract][Full Text] [Related]
6. Structural Basis of a Human Neutralizing Antibody Specific to the SARS-CoV-2 Spike Protein Receptor-Binding Domain. Yang M; Li J; Huang Z; Li H; Wang Y; Wang X; Kang S; Huang X; Wu C; Liu T; Jia Z; Liang J; Yuan X; He S; Chen X; Zhou Z; Chen Q; Liu S; Li J; Zheng H; Liu X; Li K; Yao X; Lang B; Liu L; Liao HX; Chen S Microbiol Spectr; 2021 Oct; 9(2):e0135221. PubMed ID: 34643438 [TBL] [Abstract][Full Text] [Related]
7. Antiviral Activity of Type I, II, and III Interferons Counterbalances ACE2 Inducibility and Restricts SARS-CoV-2. Busnadiego I; Fernbach S; Pohl MO; Karakus U; Huber M; Trkola A; Stertz S; Hale BG mBio; 2020 Sep; 11(5):. PubMed ID: 32913009 [TBL] [Abstract][Full Text] [Related]
8. Iota-carrageenan extracted from red algae is a potent inhibitor of SARS-CoV-2 infection in reconstituted human airway epithelia. Bovard D; van der Toorn M; Schlage WK; Constant S; Renggli K; Peitsch MC; Hoeng J Biochem Biophys Rep; 2022 Mar; 29():101187. PubMed ID: 34931176 [TBL] [Abstract][Full Text] [Related]
9. The TMPRSS2 Inhibitor Nafamostat Reduces SARS-CoV-2 Pulmonary Infection in Mouse Models of COVID-19. Li K; Meyerholz DK; Bartlett JA; McCray PB mBio; 2021 Aug; 12(4):e0097021. PubMed ID: 34340553 [TBL] [Abstract][Full Text] [Related]
10. Resveratrol and Pterostilbene Inhibit SARS-CoV-2 Replication in Air-Liquid Interface Cultured Human Primary Bronchial Epithelial Cells. Ter Ellen BM; Dinesh Kumar N; Bouma EM; Troost B; van de Pol DPI; van der Ende-Metselaar HH; Apperloo L; van Gosliga D; van den Berge M; Nawijn MC; van der Voort PHJ; Moser J; Rodenhuis-Zybert IA; Smit JM Viruses; 2021 Jul; 13(7):. PubMed ID: 34372541 [TBL] [Abstract][Full Text] [Related]
11. Designed Ankyrin Repeat Proteins: A New Class of Viral Entry Inhibitors. Walser M; Mayor J; Rothenberger S Viruses; 2022 Oct; 14(10):. PubMed ID: 36298797 [TBL] [Abstract][Full Text] [Related]
12. Neutralizing Monoclonal Antibodies That Target the Spike Receptor Binding Domain Confer Fc Receptor-Independent Protection against SARS-CoV-2 Infection in Syrian Hamsters. Su W; Sia SF; Schmitz AJ; Bricker TL; Starr TN; Greaney AJ; Turner JS; Mohammed BM; Liu Z; Choy KT; Darling TL; Joshi A; Cheng KM; Wong AYL; Harastani HH; Nicholls JM; Whelan SPJ; Bloom JD; Yen HL; Ellebedy AH; Boon ACM mBio; 2021 Oct; 12(5):e0239521. PubMed ID: 34517754 [TBL] [Abstract][Full Text] [Related]
13. Monoclonal antibodies constructed from COVID-19 convalescent memory B cells exhibit potent binding activity to MERS-CoV spike S2 subunit and other human coronaviruses. Peng Y; Liu Y; Hu Y; Chang F; Wu Q; Yang J; Chen J; Teng S; Zhang J; He R; Wei Y; Bostina M; Luo T; Liu W; Qu X; Li YP Front Immunol; 2022; 13():1056272. PubMed ID: 36618428 [TBL] [Abstract][Full Text] [Related]
14. Differential Effect of SARS-CoV-2 Spike Glycoprotein 1 on Human Bronchial and Alveolar Lung Mucosa Models: Implications for Pathogenicity. Rahman M; Irmler M; Keshavan S; Introna M; Beckers J; Palmberg L; Johanson G; Ganguly K; Upadhyay S Viruses; 2021 Dec; 13(12):. PubMed ID: 34960806 [TBL] [Abstract][Full Text] [Related]
15. Current status of antivirals and druggable targets of SARS CoV-2 and other human pathogenic coronaviruses. Artese A; Svicher V; Costa G; Salpini R; Di Maio VC; Alkhatib M; Ambrosio FA; Santoro MM; Assaraf YG; Alcaro S; Ceccherini-Silberstein F Drug Resist Updat; 2020 Dec; 53():100721. PubMed ID: 33132205 [TBL] [Abstract][Full Text] [Related]
16. Protease Inhibitors: Candidate Drugs to Inhibit Severe Acute Respiratory Syndrome Coronavirus 2 Replication. Yamaya M; Nishimura H; Deng X; Kikuchi A; Nagatomi R Tohoku J Exp Med; 2020 May; 251(1):27-30. PubMed ID: 32448818 [TBL] [Abstract][Full Text] [Related]
17. Perspectives on monoclonal antibody therapy as potential therapeutic intervention for Coronavirus disease-19 (COVID-19). Shanmugaraj B; Siriwattananon K; Wangkanont K; Phoolcharoen W Asian Pac J Allergy Immunol; 2020 Mar; 38(1):10-18. PubMed ID: 32134278 [TBL] [Abstract][Full Text] [Related]